One-Size-Fits-All Breast Cancer Screening Is Outdated—Here's What Works Better

A revolutionary approach to breast cancer screening that tailors recommendations to each woman's individual risk factors has proven more effective than the traditional one-size-fits-all method. A major study involving 46,000 women found that personalized screening based on genetics, lifestyle, and health history can reduce advanced cancers while ensuring women get exactly the amount of screening they need.

How Does Risk-Based Screening Actually Work?

The WISDOM study, coordinated by the University of California, San Francisco (UCSF), compared standard annual mammograms with an individualized approach. Researchers divided women into four risk categories using validated algorithms that considered age, genetics, lifestyle factors, health history, and breast density.

Here's how the personalized screening schedule worked:

• Lowest Risk (26% of participants): No screening until age 50 or when their calculated risk reached that of a typical 50-year-old woman
• Average Risk (62% of participants): Mammograms every two years instead of annually
• Elevated Risk (8% of participants): Annual mammogram screening as currently recommended
• Highest Risk (2% of participants): Two screenings per year, alternating between mammography and magnetic resonance imaging (MRI), regardless of age

Women in the higher risk categories also received personalized recommendations for reducing their breast cancer risk, including dietary improvements, exercise guidance, and information about risk-reducing medications.

What Did the Study Results Show?

The personalized approach did not increase the frequency of higher-stage cancers, proving it was as safe as traditional screening while being more efficient. Perhaps most telling, when women were given a choice between the two approaches, 89% chose the risk-based screening method over standard annual mammograms.

"These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," said Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and lead author of the study published in JAMA. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies."

Why Genetic Testing Changes Everything?

One of the most significant discoveries was that 30% of women who tested positive for genetic variants that increase breast cancer risk had no family history of the disease. Under current guidelines, these women would never have been offered genetic testing.

The study offered genetic testing to all participants, regardless of family history—a departure from typical practice. Beyond well-known variants like BRCA1 and BRCA2, researchers also examined smaller DNA changes that, when combined in a polygenic risk score, provide more precise risk predictions. This comprehensive genetic analysis shifted 12% to 14% of participants to different risk categories.

"This is one of the first studies to offer genetic testing to all women, regardless of family history," explained co-author Allison S. Fiscalini, MPH, director of the Athena Breast Health Network and the WISDOM study. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention."

The approach represents a fundamental shift from age-based screening to risk-based screening, acknowledging that individual breast cancer risk varies widely among women. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," noted co-author Jeffrey A. Tice, MD, a UCSF professor who develops breast cancer risk assessment tools.

The WISDOM study continues with its second phase, now enrolling women as young as 30 to identify those at risk for aggressive early cancers due to genetic variants. Since beginning in 2016, the study has enrolled more than 80,000 women, making it one of the largest breast cancer screening studies ever conducted.